Plain-English translation of NCT07344818 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called CD19 and CD20 for people with an aggressive type of blood cancer called B-cell lymphoma that has come back or stopped responding to previous treatments. involves taking some of your own immune cells, modifying them in a laboratory to better recognize and fight cancer, and then putting them back into your body. Researchers are testing different doses of this medication to find the safest and most effective level.
Many patients with aggressive B-cell lymphoma eventually stop responding to standard chemotherapy and other treatments, leaving them with very few options. This trial is exploring whether this new type of immunotherapy can help patients whose cancer has become resistant to conventional approaches.
You likely qualify if…
You likely don't qualify if…
If you qualify, researchers will collect some of your blood cells through a procedure called leukapheresis, which takes a few hours. Your cells will then be sent to a laboratory where they are modified and grown. Once ready, you will receive an infusion of these modified cells back into your body. You will need to stay in or visit the hospital for monitoring, especially in the first few weeks after the infusion, to watch for side effects and see how well the treatment is working.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Peking University People's Hospital
Collaborators
Hebei Senlang Biotechnology Co., LTD
Enrollment target
~18 participants
Started
January 2026
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaodong Mo, PhD
Peking University People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.